Externally-Funded Research Fellow (A)
School of Biomedicine
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD (as Co-Supervisor), but is currently at capacity - email supervisor to discuss availability.
Dr Adikusuma is a research scientist in Genome Editing Laboratory led by Prof Paul Thomas. He completed his PhD at the University of Adelaide under Prof Thomas supervision. He is the recipient of a fellowship from CSIRO Synthetic Biology Future Science Platform. Dr Adikusuma's research focuses on developing CRISPR gene editing techniques and strategies to improve the efficiency of the intended gene editing. His research also studies how the DNA is repaired after the cleavage by gene-editing technology. He discovered the strategies to eliminate an entire chromosome using CRISPR genome editing. Also, his landmark finding that CRISPR-Cas9 cleavage often induces large deletions (Adikusuma et al Nature 2018) cautions the biomedical community about unintended and hitherto unrecognised editing outcomes that could occur when performing germline CRISPR genome editing therapy. His research is also focused on developing highly efficient CRISPR gene editing techniques for the therapeutic of genetic diseases such as Duchenne Muscular Dystrophy, Retinitis Pigmentosa, and Cystic Fibrosis.
My research is focused on developing CRISPR genome editing technology particularly for its use in mammalian cells and in mice. I explore CRISPR strategies that promote predictable and efficient DNA editing outcomes. For example, I invented the strategies to eliminate an entire chromosome using CRISPR genome editing (Adikusuma et al Molecular Therapy 2017). My research also studies how we can efficiently and effectively create genomic mutations using CRISPR technology and develop the CRISPR tools (constructs) to achieve the goal. Additionally, I study the repair outcomes (mutations) generated after DNA breaks induced by CRISPR endonuclease. For example, we found that CRISPR-Cas9 cleavage often induces large deletions (Adikusuma et al Nature 2018). The main goal of my research is to create knowledge and technology on genome editing that is widely used for vast applications such as basic research and therapeutics. My research projects also focus on developing highly effective CRISPR therapy for genetic diseases such as Duchenne Muscular Dystrophy (DMD), Retinitis Pigmentosa, and Cystic Fibrosis. We use mammalian cells and animal preclinical models to test our CRISPR techniques in order to find the perfect formula that can effectively cure genetic diseases. Ultimately, the research is expected to develop CRISPR therapies for use in humans to provide treatments for patients.
Date Position Institution name 2018 - ongoing Research Fellow University of Adelaide, Adelaide 2017 - 2018 Postdoctoral Researcher University of Adelaide, Adelaide
Awards and Achievements
Date Type Title Institution Name Country Amount 2022 Award Early Career Researcher Executive Dean Award (2022) Faculty of Health and Medical Science Australia 2021 Award Faculty Emerging Leader Development Award Faculty of Health and Medical Science, University of Adelaide Australia 2018 Award Early Career Researcher Award SAHMRI Australia 2018 Fellowship CSIRO SynBio Fellowship CSIRO, University of Adelaide and SAHMRI Australia
Date Institution name Country Title 2011 - 2017 University of Adelaide, Adelaide Australia PhD
Year Citation 2022 Chey, Y. C. J., Arudkumar, J., Aartsma‐Rus, A., Adikusuma, F., & Thomas, P. Q. (2022). CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies. WIREs Mechanisms of Disease, 1580-1-1580-26.
2022 Burbano, L. E., Li, M., Jancovski, N., Jafar-Nejad, P., Richards, K., Sedo, A., . . . Petrou, S. (2022). Antisense oligonucleotide therapy for KCNT1 encephalopathy. JCI insight, e146090.
2021 Adikusuma, F., Lushington, C., Arudkumar, J., Godahewa, G. I., Chey, Y. C. J., Gierus, L., . . . Thomas, P. Q. (2021). Optimized nickase- and nuclease-based prime editing in human and mouse cells. Nucleic Acids Research, 49(18), 10785-10795.
DOI Scopus11 WoS10 Europe PMC3
2021 Thomson, E., Dawson, R., H'ng, C. H., Adikusuma, F., Piltz, S., & Thomas, P. Q. (2021). The Nestin neural enhancer is essential for normal levels of endogenous Nestin in neuroprogenitors but is not required for embryo development. PLoS One, 16(11), e0258538-1-e0258538-16.
DOI Scopus1 WoS1 Europe PMC1
2020 Pfitzner, C., White, M. A., Piltz, S. G., Scherer, M., Adikusuma, F., Hughes, J. N., & Thomas, P. Q. (2020). Progress Toward Zygotic and Germline Gene Drives in Mice.. CRISPR J, 3(5), 388-397.
DOI Scopus11 WoS8 Europe PMC5
2019 Prowse, T. A., Adikusuma, F., Cassey, P., Thomas, P., & Ross, J. V. (2019). A Y-chromosome shredding gene drive for controlling pest vertebrate populations. eLife, 8, e41873-1-e41873-19.
DOI Scopus22 WoS21 Europe PMC12
2018 Robertson, L., Pederick, D., Piltz, S., White, M., Nieto, A., Ahladas, M., . . . Thomas, P. Q. (2018). Expanding the RNA-Guided Endonuclease Toolkit for Mouse Genome Editing.. The CRISPR journal, 1(6), 431-439.
DOI WoS4 Europe PMC3
2018 Adikusuma, F., Piltz, S., Corbett, M. A., Turvey, M., McColl, S. R., Helbig, K. J., . . . Thomas, P. Q. (2018). Large deletions induced by Cas9 cleavage. Nature, 560(7717), E8-E9.
DOI Scopus140 WoS138 Europe PMC83
2017 Adikusuma, F., Pederick, D., McAninch, D., Hughes, J., & Thomas, P. (2017). Functional equivalence of the SOX2 and SOX3 transcription factors in the developing mouse brain and testes. Genetics, 206(3), 1495-1503.
DOI Scopus15 WoS15 Europe PMC11
2017 Adikusuma, F., Williams, N., Grutzner, F., Hughes, J., & Thomas, P. (2017). Targeted Deletion of an Entire Chromosome Using CRISPR/Cas9. Molecular Therapy, 25(8), 1736-1738.
DOI Scopus45 WoS49 Europe PMC26
2017 Van Der Hoek, K., Eyre, N., Shue, B., Khantisitthiporn, O., Glab-Ampi, K., Carr, J., . . . Beard, M. (2017). Viperin is an important host restriction factor in control of Zika virus infection. Scientific Reports, 7(1), 4475 -1-4475-14.
DOI Scopus78 WoS77 Europe PMC52
2017 Adikusuma, F., Pfitzner, C., & Thomas, P. (2017). Versatile single-step-assembly CRISPR/Cas9 vectors for dual gRNA expression. PloS one, 12(12), 1-11.
DOI Scopus18 WoS17 Europe PMC11
2014 Piltz, S., Adikusuma, F., Hughes, J., & Thomas, P. (2014). Rapid generation of mutant mice using CRISPR-mediated genome editing (tips and tricks). TRANSGENIC RESEARCH, 23(5), 867. Adikusuma, F., Lushington, C., Arudkumar, J., Godahewa, G. I., Chey, Y. C. J., Gierus, L., . . . Thomas, P. Q. (n.d.). Optimized nickase- and nuclease-based prime editing in human and mouse cells.
Year Citation 2020 Pfitzner, C., Prowse, T., Adikusuma, F., Piltz, S., Cassey, P., Ross, J., & Thomas, P. (2020). Safe development of CRISPR gene drives for invasive rodent population suppression. Poster session presented at the meeting of TRANSGENIC RESEARCH. SPRINGER. 2014 Piltz, S. G. (2014). Rapid generation of mutant mice using CRISPR mediated genome editing (tips and tricks). Poster session presented at the meeting of Transgenic Research. Ediburgh, UK: Springer.
- CSIRO SynBio fellowship for developing genome editing strategies for DMD therapeutic (2018-2021)
- Faculty Emerging Leader Development Award (2021)
- Advanced Research Platforms, Masters of Biotechnology
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2022 Co-Supervisor The Development of Novel CRISPR/Cas9 Based Therapies for Genetic Eye Disease Master of Philosophy (Medical Science) Master Full Time Miss Jesse Georgina Kennedy 2022 Co-Supervisor Designing a novel therapeutic CRISPR/Cas9 based strategy towards treating genetic eye disease Master of Philosophy (Medical Science) Master Full Time Mr Lachlan Graham Staker 2021 Co-Supervisor Improving Disease Therapy with the Application of Prime Editing Doctor of Philosophy Doctorate Full Time Mr Caleb James Lushington 2021 Co-Supervisor Development of novel CRISPR/Cas9 therapies for genetic eye disease Doctor of Philosophy Doctorate Full Time Ms Ashleigh Geiger 2020 Co-Supervisor Developing CRISPR/Cas9-Based Therapy for Duchenne Muscular Dystrophy using a Humanised Preclinical Model Doctor of Philosophy Doctorate Full Time Mr Yu Chinn Joshua Chey 2020 Co-Supervisor Development of a highly efficient CRISPR-Cas9 gene therapy strategy for precise restoration of dystrophin in Duchenne Muscular Dystrophy (DMD) Doctor of Philosophy Doctorate Full Time Mr Jayshen Christa Arudkumar
Connect With Me